Treatment of cutaneous lupus erythematosus: current approaches and future strategies.

ABSTRACT:

Purpose of review

Cutaneous lupus erythematosus (CLE) is a highly heterogeneous autoimmune disease. No specific Federal Drug Administration-approved therapies for CLE-alone are available, and resistance to conventional treatments is common. This review will summarize current treatment approaches and pending treatment strategies.

Recent findings

Research into the pathogenesis of CLE is accelerating. A skewed type I interferon production and response contribute to CLE lesions. The pathophysiology of lesions may be similar among the lesional subtypes, and patients with a more TLR9-driven disease mechanism may have more benefit from hydroxychloroquine. Case reports continue to support the use of dapsone for CLE, especially bullous lupus erythematosus. Rituximab and Belimumab hav

SUBMITTER: Shi H 

PROVIDER: S-EPMC7357847 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature